本文报告64例病毒性心肌炎的免疫状态,其中82例应用免疫核糖核酸(iRNA),17例应用左旋咪唑进行治疗观察;经iRNA治疗的病例,在治疗后3个月,结核菌素试验全部转为阳性,31/32患者其外周血液细胞免疫(羊红血球花瓣形成试验)增高,同时患者的体质亦普遍增强。iRNA组的总有效率为87.5％,左旋咪唑组为52.9％,两者有显著差异(P<0.01)。通过以上对病毒性心肌炎免疫功能的检测和两组药物治疗,作者认为提高细胞免疫力对今后病毒性心肌炎的治疗及阻断其演变为慢性病程之间的环节起着重要的作用。 This article reports the immunological status of 64 patients with viral myocarditis, of which 82 were treated with iRNA and 17 were treated with levamisole. In the iRNA-treated group, tuberculin testing was completed 3 months after treatment Positive, 31/32 patients with peripheral blood cell immunity (sheep erythrocyte petal formation test) increased, at the same time the patient’s constitution is also generally enhanced. The total effective rate was 87.5% in iRNA group and 52.9% in levamisole group (P <0.01). Through the above detection of viral myocarditis immune function and two groups of drug treatment, the authors believe that improving cellular immunity plays an important role in the future treatment of viral myocarditis and blocking its evolution to a chronic disease.